Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07776639 | May 2026 → Sep 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Yongxu Jia | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07776639 ↗ |
| Known as | QL1706 | “Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction” NCT07776639 ↗ |
| Route | Intravenous | “5 mg/kg intravenous infusion on Day 1 every 3 weeks.” NCT07776639 ↗ |